drugset / Trial / NCT04432324
Study to Evaluate the Safety and Efficacy of High Dose IVIG in Hospitalized Participants With Coronavirus Disease (COVID-19)
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of the study is to determine if high dose Intravenous IVIG plus SMT can reduce the proportion of participants dying or requiring intensive care unit (ICU) admission on or before Day 29 or who are dependent on high flow oxygen devices or invasive mechanical ventilation on Day 29 versus SMT alone in hospitalized participants with COVID-19.
Timeline
- Start
- 2020-06-02
- Primary completion
- 2021-03-03
- Completion
- 2021-03-03
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | intravenous immune globulin | Protein / enzyme biologic | 400 mg/kg | Intravenous |
| Subject | intravenous immune globulin | Protein / enzyme biologic | 500 mg/kg | Intravenous |